IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.450
AS - Asia 792
EU - Europa 716
SA - Sud America 57
Continente sconosciuto - Info sul continente non disponibili 18
AF - Africa 7
OC - Oceania 6
Totale 3.046
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.398
SG - Singapore 498
IT - Italia 363
CN - Cina 168
SE - Svezia 97
DE - Germania 86
GB - Regno Unito 64
IN - India 49
BR - Brasile 46
CA - Canada 43
FI - Finlandia 28
NL - Olanda 19
EU - Europa 18
HK - Hong Kong 15
FR - Francia 13
RO - Romania 13
BD - Bangladesh 11
JP - Giappone 10
ES - Italia 8
MX - Messico 7
UA - Ucraina 7
CZ - Repubblica Ceca 6
AU - Australia 5
IR - Iran 5
PK - Pakistan 5
TR - Turchia 5
TW - Taiwan 5
VN - Vietnam 5
CL - Cile 4
CH - Svizzera 3
EC - Ecuador 3
EG - Egitto 3
IQ - Iraq 3
RU - Federazione Russa 3
UZ - Uzbekistan 3
AR - Argentina 2
AT - Austria 2
DZ - Algeria 2
MY - Malesia 2
NP - Nepal 2
PL - Polonia 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
CO - Colombia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
KR - Corea 1
LB - Libano 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
VE - Venezuela 1
Totale 3.046
Salva come PNG Salva come JPEG
Città #
Singapore 236
Chandler 230
Santa Clara 128
Milan 110
Lawrence 106
Princeton 106
Munich 59
Wilmington 58
Chicago 51
Catanzaro 47
London 46
Ashburn 44
Des Moines 40
Beijing 35
Ottawa 28
Turku 22
Hong Kong 15
Los Angeles 15
Brooklyn 14
Guangzhou 13
Redwood City 13
Pune 12
Boardman 11
New York 11
Shanghai 11
Council Bluffs 10
Redmond 10
Rome 10
The Dalles 10
San Francisco 9
Naples 7
Columbus 6
Cosenza 6
Helsinki 6
Horia 6
Jiaxing 6
Leawood 6
Mountain View 6
Timisoara 6
Ahmedabad 5
Augusta 5
Charlotte 5
Kulgam 5
Olomouc 5
Reggio Calabria 5
San Jose 5
San Nicola Manfredi 5
Tokyo 5
Atlanta 4
Berlin 4
Dhaka 4
Hanover 4
Mexico City 4
Norwalk 4
Paris 4
San Antonio 4
Settingiano 4
São Paulo 4
Taoyuan District 4
Utrecht 4
Zhengzhou 4
Andover 3
Ankara 3
Barcelona 3
Bari 3
Castrovillari 3
Cetraro 3
Chennai 3
Clifton 3
Delhi 3
Dongyang 3
Edmonton 3
Ferrara 3
Hefei 3
Karachi 3
Kumar 3
Masera 3
Montreal 3
Mumbai 3
Nanjing 3
Rochester 3
Santo Stefano di Rogliano 3
Shenzhen 3
Tashkent 3
Toronto 3
Wuxi 3
6th of October City 2
Adams Center 2
Alexandria 2
Apo 2
Benevento 2
Bologna 2
Bosio 2
Boston 2
Brescia 2
Brugnera 2
Buffalo 2
Ceglie Del Campo 2
Duhok 2
Fayetteville 2
Totale 1.765
Salva come PNG Salva come JPEG
Nome #
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 120
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 85
miR-22 suppresses DNA ligase III addiction in multiple myeloma 84
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 62
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 56
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 55
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 54
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 52
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 49
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 49
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 47
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 46
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 43
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 41
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 41
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 41
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 41
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 40
Mir-221/222 are promising targets for innovative anticancer therapy 39
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 38
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 37
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 37
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 36
Daunorubicina liposomiale in ematologia 36
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 36
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 36
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 35
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 34
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 33
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 33
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 33
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 32
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 32
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 32
Mycosis fungoides and gastric t-cell lymphoma: A case report 32
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 32
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 31
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 31
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 31
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 30
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 29
Mouse models of Multiple Myeloma: technologic platforms and perspectives 28
The non-coding RNA landscape of plasma cell dyscrasias 28
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 27
Role of Nucleophosmin in embryionic development and tumorigenesis 26
Molecular Targets for the Treatment of Multiple Myeloma 26
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 26
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 25
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 24
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 24
Immunologic microenvironment and personalized treatment in multiple myeloma 23
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 23
MicroRNAs in multiple myeloma and related bone disease 23
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 23
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 22
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 22
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: Insights fromthe EYESHOT study 21
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress 21
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 21
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 21
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 21
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 21
Enlarging the clinical spectrum of chorea-acanthocytosis 20
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 20
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 19
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 19
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 19
Dendritic cells have the option to express IDO-mediated suppression or not 19
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 18
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 18
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 18
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 18
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 18
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 18
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 17
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 17
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 17
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 17
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 17
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 16
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 15
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells 15
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 15
New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics 15
Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability 15
miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells 15
Hedgehog pathway in myeloma pathobiology and as potential therapeutic target 15
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 15
Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety 15
Whole Body Magnetic Resonance and CT/PET in patients with multiple myeloma at staging and after treatment: personal experience in a longitudinal study 14
Emerging Role of MicroRNAs in the Pathophysiology of Immune System 14
Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential 14
miR-29b is involved in the differentiation of dendritic cells and osteoclasts from human monocytes 14
Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor 14
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients 13
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 13
Multiple myeloma-related bone disease: state-of-art and future treatments 13
Non Homologous End Joining As a New Prognostic Factor and Potential Target in Multiple Myeloma 13
Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential 13
Totale 2.916
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.598
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.598
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021200 4 1 8 10 23 12 7 20 36 35 39 5
2021/2022319 9 4 4 72 36 17 10 58 25 30 48 6
2022/2023723 223 37 33 46 69 54 4 49 103 38 51 16
2023/2024325 74 44 23 18 26 87 8 7 2 9 13 14
2024/20251.375 190 93 67 69 96 167 30 40 142 69 144 268
2025/2026127 127 0 0 0 0 0 0 0 0 0 0 0
Totale 3.174